c-peptide and Prostatic-Hyperplasia

Recent epidemiologic studies have identified obesity as a risk factor for benign prostatic hyperplasia (BPH). We examined whether adiponectin, leptin, and C-peptide were associated with incident, symptomatic BPH and whether these factors mediate the relationship between obesity and BPH risk.. Data are from Prostate Cancer Prevention Trial placebo arm participants who were free of BPH at baseline. Incident BPH (n = 698) was defined as treatment, two International Prostate Symptom Score (IPSS) values > 14, or an increase of >or=5 in IPSS from baseline documented on at least two occasions plus at least one score >or=12. Controls (n = 709) were selected from men reporting no BPH treatment or IPSS > 7 during the 7-year trial. Baseline serum was analyzed for adiponectin, C-peptide, and leptin concentrations.. Neither C-peptide nor leptin was associated with BPH risk. The odds ratio [95% CI] contrasting highest to lowest quartiles of adiponectin was 0.65[0.47, 0.87] P(trend) = 0.004. Findings differed between levels of physical activity: there was a strong inverse association between adiponectin and BPH among moderately/very active men OR = 0.43 [0.29, 0.63], and no association among sedentary/minimally active men OR = 0.92 [0.65, 1.30] P(interaction) = 0.005. Adiponectin concentrations explained only a moderate amount of the relationship between obesity and BPH risk.. High adiponectin concentrations were associated with reduced risk of incident, symptomatic BPH. This association was limited to moderately/very active men; suggesting the relationship between obesity and BPH involves a complex interaction between factors affecting glucose uptake and insulin sensitivity. However, adiponectin is likely not the only mechanism through which obesity affects BPH risk.

Topics: Adiponectin; Aged; C-Peptide; Case-Control Studies; Disease Progression; Humans; Insulin Resistance; Leptin; Male; Middle Aged; Obesity; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Washington

High concentrations of polyamines have been found in the normal human prostate. The profile of these amines appeared significantly changed in benign hypertrophy of the prostate. An increase of spermine and a fall of putrescine were always found in patients with a hypertrophied prostate weighing more than 30 g. Alterations of plasmin in these tissues seemed to reflect changes in the matrix; abnormalities of thyroid and pancreatic function documented by changes in the serum levels of TSH and c-peptide which are thought to be further evidence of a mesenchymal-epithelial interaction in the pathogenesis of benign prostate hypertrophy.

Topics: C-Peptide; Histocytochemistry; Humans; Hydrolases; Male; Peptides; Polyamines; Prostate; Prostatic Hyperplasia; Thyroid Hormones; Thyrotropin; Thyroxine; Triiodothyronine

Patients with benign hyperplasia of the prostate (BHP) were studied in relation to aberrant serum c-peptide, testosterone, estrone, cortisol and morning fasting glucose, to analyze the syntropy of diabetes and BHP. The results were compared to patients with bladder cancer without BHP and, after correction of the patients' weights and ages, the control failed to prove any significance. This is consistent with the incidence rate of maturity onset diabetes in prostate adenomas (n = 527, 7.3%) and of a control group (8.5%) of patients, 60--70 years of age. Zinc, another parameter associated with insulin function, is frequently observed to change in BHP and is significantly increased in prostatic tissue which possibly acts as a zinc pool. In this study, however, no effect of prostatectomy on serum zinc was demonstrable even in a long-term control of 9 months, suggesting a sensitive and rapid regulation of this metal independent from the prostate.

Topics: Aged; Blood Glucose; C-Peptide; Diabetes Complications; Estrone; Humans; Hydrocortisone; Male; Middle Aged; Peptides; Prostate; Prostatic Hyperplasia; Testosterone; Zinc

A series of 229 patients with urogenital carcinomas were investigated for aberrant peptide hormone activities. Serum TSH and prolactin were frequently measured in elevated levels and showed some relation to the stage of disease. Ectopic production of beta-HCG was not observed in any of the cases, thyroid and steroid hormones did not exceed the normal ranges.

Topics: Adenocarcinoma; Antibodies; C-Peptide; Cross Reactions; Female; Follicle Stimulating Hormone; Humans; Kidney Neoplasms; Luteinizing Hormone; Male; Peptides; Pituitary Hormones; Prolactin; Prostatic Hyperplasia; Prostatic Neoplasms; Thyrotropin; Urinary Bladder Neoplasms; Urogenital Neoplasms

Topics: C-Peptide; Follicle Stimulating Hormone; Humans; Kidney; Kidney Neoplasms; Male; Peptides; Polyamines; Prolactin; Prostate; Prostatic Hyperplasia; Putrescine; Spermidine; Spermine; Thyrotropin

Patients with benign hyperplasia of the prostate and with anaplastic carcinoma have similar activities in their cells in staining for acid phosphatase. After therapy with estrogens the acid phosphatase is significantly inhibited, leucin amino peptidase and succinate dehydrogenase appear to be reactivated in the cells of anaplastic carcinoma. Serum TSH is decreased distinctly, serum levels of LH and prolactin are significantly elevated especially in patients with anaplastic carcinoma of the prostate in comparison to that of patients with treated benign hyperplasia.

Topics: Acid Phosphatase; C-Peptide; Carcinoma; Enzymes; Estrogens; Fibrinolysin; Follicle Stimulating Hormone; Hormones; Humans; Leucyl Aminopeptidase; Luteinizing Hormone; Male; Prolactin; Prostatic Hyperplasia; Prostatic Neoplasms; Succinate Dehydrogenase; Thyrotropin